Clinical trials
Completed Coronary Disease trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
71 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 4 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 12 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 8 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 8 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 71 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| China National Center for Cardiovascular Diseases | 6 |
| Abbott Medical Devices | 3 |
| The First Affiliated Hospital with Nanjing Medical University | 3 |
| GlaxoSmithKline | 2 |
| Guang'anmen Hospital of China Academy of Chinese Medical Sciences | 2 |
| Hoffmann-La Roche | 2 |
| Insight Lifetech Co., Ltd. | 2 |
| Nanjing First Hospital, Nanjing Medical University | 2 |
| Prof. Stephen Lee | 2 |
| Shanghai MicroPort Medical (Group) Co., Ltd. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Coronary Disease | 71 |
| Coronary Artery Disease | 14 |
| Cardiovascular Diseases | 10 |
| Myocardial Ischemia | 10 |
| Heart Diseases | 8 |
| Angina Pectoris | 5 |
| Arteriosclerosis | 5 |
| Vascular Diseases | 5 |
| Acute Coronary Syndrome | 4 |
| Angina, Stable | 4 |
Trials
Showing 1 to 25 of 71. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.